Table 1

Baseline demographics

Total
(n=188)
Age, years: median (range)59 (19–89)
Male, number (%)95 (51)
Race, number (%)
 White168 (89.4)
 Asian13 (6.9)
 Hispanic3 (1.6)
 Black1 (0.5)
 Other3 (1.6)
Disease duration, years: median (range)5.0 (0.4–34.5)
Prior treatment with cyclophosphamide
 Number of patients (%)149 (79.3)
 Cumulative dose, grams (g): median (range)9 (0.15–301)
Prior rituximab therapy
 Number of patients (%)67 (35.6)
 Cumulative dose, grams (g): median (range)3910 (1000–16000)
Glucocorticoid induction regimen, number (%)
 1 mg/kg/day starting dose (1A)54 (28.7)
 0.5 mg/kg/day starting dose (1B)134 (71.3)
ANCA type, number (%)
 Antiproteinase 3137 (72.9)
 Antimyeloperoxidase51 (27.1)
Relapse type on entry into trial, number (%)
 Severe119 (63.3)
 Non-severe69 (36.7)
BVAS/WG: median (range)5 (3–14)
  • ANCA, antineutrophil cytoplasmic antibody; BVAS/WG, Birmingham Vasculitis Activity Score for Wegener's granulomatosis.